Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

, Amicus recognized $0.7 million of the Shire upfront payment and $3.7 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 through 5 and are primarily due to pre-tax stock compensation expense.

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

    (1) Stock option expense -- Non-GAAP net loss and diluted net loss per
        common share exclude the impact of the stock option expense recorded
        in accordance with SFAS No. 123R. Amicus believes that excluding the
        impact of expensing stock options better reflects the recurring
        economic characteristics of its business.

    (2) Other items -- Non-GAAP net loss and diluted net loss per common share
        exclude other unusual or non-recurring items that are evaluated on an
        individual basis. Amicus' evaluation of whether to exclude an item for
        purposes of determining its non-GAAP financial measures considers both
        the quantitative and qualitative aspects of the item, including, among
        other things (i) its size and nature, (ii) 
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... 19, 2014 Charm Sciences is pleased ... the Detection of Aflatoxin M1 in raw commingled milk ... third party validation. The peer reviewed report of the ... Institute for Agricultural and Fisheries Research (ILVO-T&V) has been ... Aflatoxin B1, the most toxic aflatoxin and a known ...
(Date:12/19/2014)... 19, 2014  Roche (SIX: RO, ROG; OTCQX: RHHBY) ... (Bina), a privately held company based in ... provides a big data platform for centralized management ... Bina,s proprietary on-market Genomic Management Solution, Bina-GMS 1 ... perform fast and scalable analyses to maximize the ...
Breaking Biology Technology:Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... A new post-hoc sub-analysis of an important set of ... as the "core clinical cohort" population – showed that ... with a 26 percent relative risk reduction in the ... stroke, compared to treatment with clopidogrel (8.3 percent vs. ...
... National Institute of Standards and Technology (NIST), George ... made nano-sized sensors that detect volatile organic compoundsharmful ... productsthat offer several advantages over today,s commercial gas ... to detect one or several compounds over a ...
... automatic and portable detector that takes just fifteen minutes ... is being developed by US researchers. The technology amplifies ... reveal the presence of just 40 microscopic cells of ... known as anthrax, is a potentially lethal microbe that ...
Cached Biology Technology:Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8Nanowire-based sensors offer improved detection of volatile organic compounds 2Nano detector for deadly anthrax 2
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced ... America Perimeter Security Systems Market" report to their ... The North American perimeter security market is estimated ... to 2019. Although the U.S. market holds a larger ... is expected to grow at a higher CAGR of ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... 2013 - BGI Health and ACIBADEM Healthcare Group ... Molecular Biology, signed a Memorandum of Understanding (MoU) ... to Turkey and improving Turkish reproductive healthcare. This ... technologies in the areas of Monogenic disorders, personalized ...
... do woolly mammoths wandering around the ancient spruce ... with predicting how species could respond to climate ... Center for Environmental Science,s Appalachian Laboratory, along with ... University of California-Merced, have received a three-year, $670,000 ...
... do nerve cells -- which can each be up to ... falling apart? Axons, the long, cable-like projections on neurons, ... molecular building block of the cell skeleton. The finding, which ... was reported in the April 10 issue of Neuron ...
Cached Biology News:BGI Health forms partnership with ACIBADEM hospital on genetic disease testing 2Scientists look to ancient past to better predict how species may respond climate change 2Scientists learn what makes nerve cells so strong 2
...
... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...
... Activity Kit ADAM17 Activity Kit TNF-α Converting ... PROTECT FROM LIGHT. AVOID FREEZE/THAW CYCLES. The ... and sensitive assay designed to measure human ... samples and for screening enzyme inhibitors. An ...
... DNA Modification Kit contains reagents required to ... sample. In the bisulfite reaction, all unmethylated ... to uracils, while 5-methylcytosines remain unaltered. Thus, ... differ depending on whether the DNA is ...
Biology Products: